ECOG-ACRIN E5103

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Breast

Status:

Closed

A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer

 

E5103 Step 3 registration, registration to the EL112LAB substudy, will close to accrual on July 29, 2016.

NCT#00433511